Martin T. King, MD, PhD, summarizes the findings of three studies presented at ASTRO 2023, starting with the PACE-B study. The PACE-B study compared radiation therapies for patients with favorable-risk prostate cancer and found that stereotactic body radiation therapy (SBRT) in 5 fractions yielded similar oncologic outcomes to conventional methods, though with potential increased long-term genitourinary toxicity.
The FORMULA-509 trial focused on recurrent prostate cancer after prostatectomy, suggesting that adding abiraterone and apalutamide to androgen-deprivation therapy improved progression-free survival, especially for patients with a PSA level ≥ 0.5. Finally, the FASTRACK II study demonstrated the efficacy of SBRT for medically inoperable renal cell carcinoma, achieving 100% local control at 43 months with a relatively low risk for grade 3 toxicity, making it a recommended treatment for such patients.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASTRO 2023: A Trio of Studies With Potential Clinical Implications - Medscape - Oct 19, 2023.
Comments